IL18 and neoplasm: Further support for this therapeutic approach comes from the strong antitumour effects achieved through tumour expression/local delivery of other proinflammatory cytokines including IL-2 [69], granulocyte macrophage-colony stimulating factor (GM-CSF) [70], and IL-18 alone [71] or a combination with IL-12 [72] which have been reported in preclinical in vivo models of PCa.